Tdspharm Co., Ltd. (KOSDAQ:464280)
South Korea · Delayed Price · Currency is KRW 8,280.00
+280.00 (3.50%)
Apr 8, 2026, 3:30 PM KST
Tdspharm Revenue
In the year 2025, Tdspharm had annual revenue of 27.62B KRW with 0.37% growth. Tdspharm had revenue of 8.68B in the quarter ending December 31, 2025, with 54.47% growth.
Revenue
27.62B
Revenue Growth
+0.37%
P/S Ratio
1.66
Revenue / Employee
n/a
Employees
n/a
Market Cap
45.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.62B | 102.10M | 0.37% |
| Dec 31, 2024 | 27.52B | -2.53B | -8.42% |
| Dec 31, 2023 | 30.05B | 4.46B | 17.43% |
| Dec 31, 2022 | 25.59B | 5.77B | 29.11% |
| Dec 31, 2021 | 19.82B | 1.80B | 9.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Sam Chun Dang Pharm. | 231.81B |
| ALTEOGEN | 215.86B |
| BCWORLD PHARM. | 75.80B |
| Aprogen Biologics | 73.23B |
| METACARE CO. | 32.82B |
| HASS Corp. | 16.59B |